Ophthalmology. Glaucoma · 2026
Adverse Events and Intraocular Pressure-Lowering Effect of Topical 0.5% Apraclonidine in Childhood Glaucoma: A Retrospective Single-Center Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elhusseiny Abdelrahman M, Macaron Marie Michele, Hassan Amr K, Chang Ta C
Аннотация
PURPOSE: To evaluate the adverse events and intraocular pressure (IOP)-lowering effects of topical apraclonidine in childhood glaucoma management.
DESIGN: A retrospective case series.
PARTICIPANTS: Glaucoma patients aged ≤18 years who had received topical apraclonidine.
METHODS: We extracted data on demographics, ocular and systemic adverse events, and IOP reduction. We defined and classified childhood glaucoma based on the Childhood Glaucoma Research Network criteria.
MAIN OUTCOME MEASURES: Adverse events and IOP-lowering effect of topical 0.5% apraclonidine.
RESULTS: We included 108 eyes (90 patients). Glaucoma associated with non-acquired systemic disease or syndrome (36 eyes, 33.3%) was the most common diagnosis, followed by glaucoma following cataract surgery (29 eyes, 26.9%). The median age at glaucoma diagnosis was 32 months (interquartile range [IQR]: 5.3-68.5 months). The median age at the start of apraclonidine was 5 years (IQR = 3-9). The mean number of glaucoma medications on apraclonidine initiation was 2.7 ± 0.8. The median duration for apraclonidine use was 327 days (IQR = 42-665). There were no local adverse events reported, and only 2 cases of systemic adverse events (1 case [1.1%] of night terror and 1 case [1.1%] of somnolence). The mean baseline IOPs was 30 ± 4.6 mmHg (n = 85 eyes), with a mean IOP reduction of 5.3 mmHg at 6 months after use (n = 20 eyes).
CONCLUSIONS: Topical apraclonidine use demonstrated a low rate of reported adverse events and was associated with clinically meaningful IOP reduction as an adjunctive treatment in childhood glaucoma.
FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.
DESIGN: A retrospective case series.
PARTICIPANTS: Glaucoma patients aged ≤18 years who had received topical apraclonidine.
METHODS: We extracted data on demographics, ocular and systemic adverse events, and IOP reduction. We defined and classified childhood glaucoma based on the Childhood Glaucoma Research Network criteria.
MAIN OUTCOME MEASURES: Adverse events and IOP-lowering effect of topical 0.5% apraclonidine.
RESULTS: We included 108 eyes (90 patients). Glaucoma associated with non-acquired systemic disease or syndrome (36 eyes, 33.3%) was the most common diagnosis, followed by glaucoma following cataract surgery (29 eyes, 26.9%). The median age at glaucoma diagnosis was 32 months (interquartile range [IQR]: 5.3-68.5 months). The median age at the start of apraclonidine was 5 years (IQR = 3-9). The mean number of glaucoma medications on apraclonidine initiation was 2.7 ± 0.8. The median duration for apraclonidine use was 327 days (IQR = 42-665). There were no local adverse events reported, and only 2 cases of systemic adverse events (1 case [1.1%] of night terror and 1 case [1.1%] of somnolence). The mean baseline IOPs was 30 ± 4.6 mmHg (n = 85 eyes), with a mean IOP reduction of 5.3 mmHg at 6 months after use (n = 20 eyes).
CONCLUSIONS: Topical apraclonidine use demonstrated a low rate of reported adverse events and was associated with clinically meaningful IOP reduction as an adjunctive treatment in childhood glaucoma.
FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.